These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31532479)

  • 1. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era.
    Vasudevan A; Ip F; Liew D; van Langenberg DR
    Inflamm Bowel Dis; 2020 Feb; 26(3):369-379. PubMed ID: 31532479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
    Holko P; Kawalec P; Pilc A
    Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
    Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
    J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease.
    Bolin K; Hertervig E; Louis E
    J Crohns Colitis; 2019 Sep; 13(10):1323-1333. PubMed ID: 30893421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
    Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
    Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
    J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.
    Bodger K; Kikuchi T; Hughes D
    Aliment Pharmacol Ther; 2009 Aug; 30(3):265-74. PubMed ID: 19438428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
    Vuijk SA; Jongsma MME; Hoeven BM; Cozijnsen MA; van Pieterson M; de Meij TGJ; Norbruis OF; Groeneweg M; Wolters VM; van Wering H; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg S; Rizopoulos D; Poley MJ; Escher JC; de Ridder L
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1510-1520. PubMed ID: 38644588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
    Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.
    Catt H; Bodger K; Kirkham JJ; Hughes DA
    Pharmacoeconomics; 2019 Dec; 37(12):1509-1523. PubMed ID: 31372948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn's Disease.
    Bashir NS; Walters TD; Griffiths AM; Ito S; Ungar WJ
    Inflamm Bowel Dis; 2020 Jul; 26(8):1239-1250. PubMed ID: 31728510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China.
    Chen H; Shi J; Pan Y; Zhang Z; Fang H; Chen Y; Chen W; Cao Q
    Adv Ther; 2020 Jan; 37(1):431-449. PubMed ID: 31797196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease.
    Vasudevan A; Gibson PR; Van Langenberg DR
    Inflamm Bowel Dis; 2019 Aug; 25(9):1462-1473. PubMed ID: 30689858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy.
    Alizadeh ER; Dervieux T; Vermeire S; Dubinsky M; D'Haens G; Laharie D; Shim A; Vaughn BP
    Pharmacotherapy; 2024 Apr; 44(4):331-342. PubMed ID: 38576238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
    Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
    Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
    Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
    J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China.
    Zhou T; Sheng Y; Guan H
    Adv Ther; 2021 Aug; 38(8):4233-4245. PubMed ID: 34089502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J; Punekar YS; Morris J; Chung-Faye G
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.